Organic Letters
Letter
oxime moiety, could be synthesized by heating a mixture of 3e
and 1,3-dipolarophile, alkyne, and alkene according to the
relevant literature.49 Isoxazole 32, lacking the oxime group
versus 29, could be generated from the same starting furoxan
3e by changing the solvent.50 Thus, functional groups with a
diverse range of size, electronic nature, and hydrogen bonding
ability are easily installed using a carboxylic acid as a synthetic
handle.
In conclusion, we have developed radical addition reactions
to furoxans in which the carbon radical is generated from
carboxylic acids in the presence of a silver catalyst and
persulfate salt. The present strategy enables a rare C−C bond
formation on the furoxan ring. Furthermore, we demonstrated
that the generated furoxans can be transformed to a variety of
functional groups by taking advantage of the lability of the
furoxan ring. Hence, furoxan “build-and-scrap” strategy
provides a powerful method to convert carboxylic acids to a
variety of functional groups in short steps. The expansion of
this strategy to other common functional groups and the
development of other “scrap” methods of furoxans are in
progress in our laboratory.
Masahiko Hayashi − Department of Chemistry, Graduate
School of Science, Kobe University, Kobe 657-8501, Japan;
Masahiro Yamanaka − Department of Chemistry and Research
Center for Smart Molecules, Rikkyo University, Tokyo 171-
Takao Tsuneda − Graduate School of Science, Technology and
Innovation, Kobe University, Kobe 657-8501, Japan;
Complete contact information is available at:
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
■
This work was financially supported by JSPS KAKENHI Grant
Nos. JP16K18844 and JP17J00025, Futaba Electronics
Memorial Foundation, Suzuken Memorial Foundation, In-
amori Foundation, and Daiichi Sankyo Foundation of Life
Science.
ASSOCIATED CONTENT
* Supporting Information
■
sı
REFERENCES
■
The Supporting Information is available free of charge at
(1) Pitt, W. R.; Parry, D. M.; Perry, B. G.; Groom, C. R. J. Med.
Chem. 2009, 52, 2952−2963.
(2) Paton, R. M., Product Class 7:1,2,5-Oxadiazoles. In Science of
Synthesis; Storr, R. C., Gilchrist, T. L., Eds.; Georg Thieme Verlag:
Stuttgart, 2004; Vol. 13, pp 185−218.
Experimental procedures, characterization data, DFT
calculations, crystallographic data, and NMR spectra
(3) Makhova, N. N.; Kulikov, A. S. Russ. Chem. Rev. 2013, 82,
1007−1033.
Accession Codes
(4) Fershtat, L. L.; Makhova, N. N. Russ. Chem. Rev. 2016, 85,
1097−1145.
tallographic data for this paper. These data can be obtained
Cambridge Crystallographic Data Centre, 12 Union Road,
Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
(5) Sheremetev, A. B.; Makhova, N. N.; Friedrichsen, W.,
Monocyclic furazans and furoxans. In Advances in Heterocyclic
Chemistry; Academic Press, 2001; Vol. 78, pp 65−188.
(6) Nikonov, G.; Bobrov, S., 5.05 - 1,2,5-Oxadiazoles. In
Comprehensive Heterocyclic Chemistry III; Katritzky, A. R., Ramsden,
C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Oxford, 2008;
Vol. 5, pp 315−395.
AUTHOR INFORMATION
Corresponding Author
■
(7) Gasco, A.; Boulton, A. J., Furoxans and Benzofuroxans. In
Advances in Heterocyclic Chemistry; Katritzky, A. R., Boulton, A. J.,
Eds.; Academic Press, 1981; Vol. 29, pp 251−340.
Ryosuke Matsubara − Department of Chemistry, Graduate
School of Science, Kobe University, Kobe 657-8501, Japan;
́
(8) Cerecetto, H.; Gonzalez, M., Benzofuroxan and Furoxan.
Chemistry and Biology. In Bioactive Heterocycles IV. Topics in
Heterocyclic Chemistry; Khan, M. T. H., Ed.; Springer: Berlin, 2007;
Vol. 10, pp 265−308.
́
(9) Kekule, A. Ann. Chem. Pharm. 1857, 101, 200−213.
Authors
(10) Wieland, H. Justus Liebigs Ann. Chem. 1903, 329, 225−268.
(11) Ghigo, D.; Calvino, R.; Heller, R.; Calvino, R.; Alessio, P.;
Fruttero, R.; Gasco, A.; Bosia, A.; Pescarmona, G. Biochem. Pharmacol.
1992, 43, 1281−1288.
Hojin Kim − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
Takaya Sakaguchi − Department of Chemistry, Graduate
School of Science, Kobe University, Kobe 657-8501, Japan
Weibin Xie − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
Xufeng Zhao − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
Yuto Nagoshi − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
Chaoyu Wang − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
Masahiro Tateiwa − Department of Chemistry, Graduate
School of Science, Kobe University, Kobe 657-8501, Japan
Akihiro Ando − Department of Chemistry, Graduate School of
Science, Kobe University, Kobe 657-8501, Japan
̈
(12) Feelisch, M.; Schonafingeri, K.; Noack, H. Biochem. Pharmacol.
1992, 44, 1149−1157.
(13) Calvino, R.; Fruttero, R.; Ghigo, D.; Bosia, A.; Pescarmona, G.
P.; Gasco, A. J. Med. Chem. 1992, 35, 3296−3300.
(14) Medana, C.; Ermondi, G.; Fruttero, R.; Di Stilo, A.; Ferretti, C.;
Gasco, A. J. Med. Chem. 1994, 37, 4412−4416.
(15) Very recently, diacylfuroxans were reported to have GPX4
inhibitory activities: Eaton, J. K.; Ruberto, R. A.; Kramm, A.;
Viswanathan, V. S.; Schreiber, S. L. J. Am. Chem. Soc. 2019, 141,
20407−20415.
(16) Matsubara, R.; Eguchi, S.; Ando, A.; Hayashi, M. Org. Biomol.
Chem. 2017, 15, 1965−1969.
(17) Matsubara, R.; Ando, A.; Hayashi, M. Tetrahedron Lett. 2017,
58, 3337−3340.
E
Org. Lett. XXXX, XXX, XXX−XXX